See the DrugPatentWatch profile for amphetamine
Dextroamphetamine Extended-Release (ER) is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy [1][2]. It works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain, which helps improve focus and reduce impulsivity [3].
What is the typical dosage for Dextroamphetamine ER?
Dosage for Dextroamphetamine ER is individualized and depends on the patient's response and tolerance [4]. Treatment usually starts with a low dose, which is then gradually increased [4]. For ADHD, the recommended starting dose for adults and children 6 years and older is typically 10 mg once daily, with doses adjusted in increments of 5 to 10 mg weekly as needed [4]. For narcolepsy, the starting dose is also often 10 mg daily, with adjustments made as necessary [4].
How does Dextroamphetamine ER work?
Dextroamphetamine ER's mechanism of action involves influencing the dopaminergic and noradrenergic systems in the brain [3]. It is thought to block the reuptake of dopamine and norepinephrine, and also to promote their release from nerve terminals [3]. This increased availability of these neurotransmitters in the synaptic cleft is believed to be responsible for its therapeutic effects in managing ADHD and narcolepsy symptoms [3].
What are the potential side effects of Dextroamphetamine ER?
Common side effects of Dextroamphetamine ER can include decreased appetite, dry mouth, weight loss, insomnia, stomach pain, nervousness, and increased blood pressure [1][5]. Less common but more serious side effects may involve cardiovascular issues such as heart palpitations, rapid heart rate, or chest pain, as well as psychiatric symptoms like hallucinations or mania [1][5]. Long-term use may also lead to dependence [5].
When does the patent for Dextroamphetamine ER expire?
Information regarding specific patent expiry dates for Dextroamphetamine ER can vary depending on the formulation and manufacturer [6]. DrugPatentWatch.com provides a database that can be consulted for detailed patent information on specific drug products [6]. Generally, extended-release formulations often have patents that protect them for a period following their approval, aiming to allow for recoupment of research and development costs [7].
Are there alternative treatments for ADHD and narcolepsy?
Yes, several alternative treatments exist for ADHD and narcolepsy. For ADHD, these include other stimulant medications (e.g., methylphenidate-based drugs), non-stimulant medications (e.g., atomoxetine, guanfacine), and behavioral therapies [8]. For narcolepsy, treatment options can include stimulant medications, wakefulness-promoting agents like modafinil, and other medications to manage specific symptoms such as cataplexy [9].
What is the difference between Dextroamphetamine ER and immediate-release dextroamphetamine?
The primary difference lies in their release profiles and duration of action. Immediate-release (IR) dextroamphetamine is taken multiple times a day and provides rapid symptom relief, but its effects are shorter-lived [10]. Extended-release (ER) formulations are designed to release the medication gradually over a longer period, allowing for once-daily dosing and sustained symptom control throughout the day [10].
Who manufactures Dextroamphetamine ER?
Several pharmaceutical companies manufacture Dextroamphetamine ER, including brands like Dexedrine Spansule and others [1]. Generic versions are also available from various manufacturers.
---
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK551572/
[2] https://www.webmd.com/drugs/2/drug-16627/dextroamphetamine-er-oral/details
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175050/
[4] https://www.rxlist.com/dexedrine-spansule-drug.htm
[5] https://www.mayoclinic.org/drugs-supplements/dextroamphetamine-oral-route/side-effects/drug-20074773
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cd-er/understanding-differences-brand-and-generic-drugs
[8] https://www.cdc.gov/ncbddd/adhd/treatment.html
[9] https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071731/